@article{LachaudCastorHainetal.2014,
  author    = {Lachaud, Christophe and Castor, Dennis and Hain, Karolina and Mu{\~n}oz, Ivan and Wilson, Jamie and MacArtney, Thomas J. and Schindler, Detlev and Rouse, John},
  title     = {Distinct functional roles for the two SLX4 ubiquitin-binding UBZ domains mutated in Fanconi anemia},
  series = {Journal of Cell Science},
  volume    = {127},
  journal   = {Journal of Cell Science},
  number    = {13},
  issn      = {1477-9137},
  doi       = {10.1242/jcs.146167},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-120908},
  pages     = {2811-7},
  year      = {2014},
  abstract  = {Defects in SLX4, a scaffold for DNA repair nucleases, cause Fanconi anemia due to defective repair of inter-strand DNA crosslinks (ICLs). Some FA patients have an SLX4 deletion removing two tandem UBZ4-type ubiquitin-binding domains, implicated in protein recruitment to sites of DNA damage. Here we show that human SLX4 is recruited to sites of ICL induction but the UBZ-deleted form of SLX4 in cells from FA patients is not. SLX4 recruitment does not require ubiquitination of FANCD2, or the E3 ligases RNF8, RAD18 and BRCA1. We show that the first (UBZ-1), but not the second UBZ domain of SLX4 binds to ubiquitin polymers with a preference for K63-linked chains. Furthermore, UBZ-1 is required for SLX4 recruitment to ICL sites, and for efficient ICL repair in murine fibroblasts. SLX4 UBZ-2 domain does not bind ubiquitin in vitro or contribute to ICL repair, but it is required for resolution of Holliday junctions in vivo. These data shed light on SLX4 recruitment, and suggest that there remain to be identified ubiquitinated ligands and E3 ligases critical for ICL repair.},
  language  = {en}
}
@article{KohlhaseBogdanovaSchuermannetal.2014,
  author    = {Kohlhase, Sandra and Bogdanova, Natalia V. and Sch{\"u}rmann, Peter and Bermisheva, Marina and Khusnutdinova, Elza and Antonenkova, Natalia and Park-Simon, Tjoung-Won and Hillemanns, Peter and Meyer, Andreas and Christiansen, Hans and Schindler, Detlev and D{\"o}rk, Thilo},
  title     = {Mutation Analysis of the ERCC4/FANCQ Gene in Hereditary Breast Cancer},
  series = {PLOS ONE},
  volume    = {9},
  journal   = {PLOS ONE},
  number    = {1},
  doi       = {10.1371/journal.pone.0085334},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-117582},
  pages     = {e85334},
  year      = {2014},
  abstract  = {The ERCC4 protein forms a structure-specific endonuclease involved in the DNA damage response. Different cancer syndromes such as a subtype of Xeroderma pigmentosum, XPF, and recently a subtype of Fanconi Anemia, FA-Q, have been attributed to biallelic ERCC4 gene mutations. To investigate whether monoallelic ERCC4 gene defects play some role in the inherited component of breast cancer susceptibility, we sequenced the whole ERCC4 coding region and flanking untranslated portions in a series of 101 Byelorussian and German breast cancer patients selected for familial disease (set 1, n = 63) or for the presence of the rs1800067 risk haplotype (set 2, n = 38). This study confirmed six known and one novel exonic variants, including four missense substitutions but no truncating mutation. Missense substitution p.R415Q (rs1800067), a previously postulated breast cancer susceptibility allele, was subsequently screened for in a total of 3,698 breast cancer cases and 2,868 controls from Germany, Belarus or Russia. The Gln415 allele appeared protective against breast cancer in the German series, with the strongest effect for ductal histology (OR 0.67; 95\%CI 0.49; 0.92; p = 0.003), but this association was not confirmed in the other two series, with the combined analysis yielding an overall Mantel-Haenszel OR of 0.94 (95\% CI 0.81; 1.08). There was no significant effect of p.R415Q on breast cancer survival in the German patient series. The other three detected ERCC4 missense mutations included two known rare variants as well as a novel substitution, p.E17V, that we identified on a p.R415Q haplotype background. The p.E17V mutation is predicted to be probably damaging but was present in just one heterozygous patient. We conclude that the contribution of ERCC4/FANCQ coding mutations to hereditary breast cancer in Central and Eastern Europe is likely to be small.},
  language  = {en}
}
@article{vonBernuthRavindranDuetal.2014,
  author    = {von Bernuth, Horst and Ravindran, Ethiraj and Du, Hang and Froehler, Sebastian and Strehl, Karoline and Kraemer, Nadine and Issa-Jahns, Lina and Amulic, Borko and Ninnemann, Olaf and Xiao, Mei-Sheng and Eirich, Katharina and Koelsch, Uwe and Hauptmann, Kathrin and John, Rainer and Schindler, Detlev and Wahn, Volker and Chen, Wei and Kaindl, Angela M.},
  title     = {Combined immunodeficiency develops with age in Immunodeficiency-centromeric instability-facial anomalies syndrome 2 (ICF2)},
  series = {Orphanet Journal of Rare Dieeases},
  volume    = {9},
  journal   = {Orphanet Journal of Rare Dieeases},
  doi       = {10.1186/s13023-014-0116-6},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-114859},
  pages     = {116},
  year      = {2014},
  abstract  = {The autosomal recessive immunodeficiency-centromeric instability-facial anomalies syndrome (ICF) is characterized by immunodeficiency, developmental delay, and facial anomalies. ICF2, caused by biallelic ZBTB24 gene mutations, is acknowledged primarily as an isolated B-cell defect. Here, we extend the phenotype spectrum by describing, in particular, for the first time the development of a combined immune defect throughout the disease course as well as putative autoimmune phenomena such as granulomatous hepatitis and nephritis. We also demonstrate impaired cell-proliferation and increased cell death of immune and non-immune cells as well as data suggesting a chromosome separation defect in addition to the known chromosome condensation defect.},
  language  = {en}
}